TX-FORTERRO
17.2.2021 10:02:16 CET | Business Wire | Press release
Forterro , a group of companies that deliver enterprise resource planning (ERP) software to small- and medium-sized businesses, today announced the appointment of two new executives to lead the company into a new phase of growth in its core market, Europe.
Dean Forbes, a longtime, U.K.-based software executive who was most recently the president of The Access Group, was named Forterro’s chief executive. Paul Smolinski, the former chief financial officer of HR and payroll software firm CoreHR, was named CFO. The two U.K.-based leaders have been tapped to continue Forterro’s growth strategy in Europe, working with the company’s strategic leadership teams across the group’s primary business units in France, Germany, Poland, Sweden, and Switzerland.
Forbes joins Forterro after an extensive career in executive and senior leadership roles for a number of international software companies. Most recently he led the growth and expansion of CoreHR, a UK HCM software provider, across Europe. CoreHR was acquired by The Access Group, where Forbes subsequently served as president and executive board member. Prior to CoreHR, Forbes was CEO of Paris-headquartered SaaS software company KDS, where he led the successful growth and international expansion of the firm, leading to its acquisition by American Express. Earlier in his career, Forbes held senior leadership roles at Philadelphia HQ’d Primavera Systems and, subsequently, Oracle where he was global vice president for sales and marketing for the PPM Division. Forbes brings this wealth of experience to Forterro and its acquired companies, which include abas Software (Germany); BPSC (Poland); Clip Industrie, Silog and Sylob (France); Jeeves and Infocube (Sweden); and ProConcept (Switzerland). Forterro is backed by global, technology-focused investment firm Battery Ventures.
“I am thrilled to become part of such a strong group of ERP companies, who are all successfully operating in one of the strongest, most steadily growing markets in enterprise software,” Forbes said. “The cornerstone of our ongoing success will be to continue investing in the market leadership positions of local and niche ERP software businesses throughout Europe. I am excited about leading the next stage of the Forterro journey as we look to continue to grow the business aggressively, both organically and through further acquisitions.”
“Bringing in new, Europe-based leadership is part of the natural evolution of Forterro,” said Dave Tabors, a Forterro board member and Battery Ventures private equity partner. “Former CEO Jeff Tognoni, former COO Scott Malia, and the rest of the U.S.-based Forterro leadership team have done an outstanding job of growing the business by evaluating, acquiring, and operating ERP companies. To push Forterro into its next stage of development, however, it is time to cultivate leadership talent in closer proximity to our business unit operations. We are very excited to work with Dean as he prepares Forterro for its next stage of growth.”
“We have spent the last several years working closely with our counterparts in Europe to build sustainable growth strategies and unique operating approaches for each business unit and product market,” added Jeff Tognoni, who is stepping down after leading Forterro and growing revenue more than seven-fold since the initial acquisition of Jeeves Information Systems in 2012. “The strength of our local teams and their businesses lets me know that part of our job is done, and that Forterro is ready for new challenges and continued success under the leadership of Dean and Paul.”
ABOUT FORTERRO
Forterro is a group of companies that deliver ERP software to SMEs in specialized geographical or vertical markets. Backed by the investment of Battery Ventures , Forterro operates business units in Sweden, Switzerland, France, Poland, and Germany, as well as regional office locations and research and development centers around the world. Through its ever-growing ecosystem of IP and capital, Forterro collaborates with local management teams to strengthen the solution offerings and operational performance of its portfolio companies. For more information, visit www.forterro.com .
ABOUT BATTERY VENTURES
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Herzliya, Israel; London; and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005237/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom